Supplemental Table 1. PI and NRTI use by HIV-infected individuals (n=20)

PI	
Norvir, %	50
Lopinavir, %	20
Atazanavir, %	15
Saquinavir, %	10
Darunavir, %	10
Fosamprenavir, %	10
NRTI	
Tenofovir, %	50
Lamivudine, %	45
Abacavir, %	35
Emtricitabine, %	35
Zidovudine, %	10

Data reported as percentage.
Abbreviations: PI, protease inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitors

Supplemental Table 2. Baseline Demographic and Clinical Characteristics of Non-HIV and HIV-infected Individuals

	Non-HIV-Infected (n=10)	HIV-Infected (n=20)	P Value
Demographics			
Age (years)	52±2	49±2	0.34
Race (%)			0.27
Caucasian	80	45	
African American	20	35	
Other	0	20	
Male Sex (%)	70	65	0.78
HIV Parameters			
CD4$^+$ T cell count (cells/μL)	N/A	571±73	--
Log HIV RNA Viral Load (copies/mL)	N/A	1.77±0.19	--
Duration HIV (years)	N/A	18±1	--
Duration ART use (years)	N/A	11±1	--
Current PI use (%)	N/A	60	--
Current NRTI use (%)	N/A	90	--
Current NNRTI use (%)	N/A	25	--
History of HCV infection (%)	0	20	0.13
Body Composition and Metabolic Parameters			
Iliac Waist Circumference (cm)	89±4	94±3	0.40
BMI(kg/m^2)	25±1	26±1	0.50
BAI (%fat)	44±3	48±3	0.29
VAT (cm^2)	140 [84,184]	134 [56,188]	0.98
SAT (cm^2)	213 [122,269]	209 [107,342]	0.91
TAT (cm^2)	342 [245, 474]	385 [233, 540]	0.88
Total Cholesterol (mg/dL)	173±11	181±8	0.57
HOMA-IR	0.59 [0.35,1.59]	0.98 [0.58,1.85]	0.21
Creatinine (mg/dL)	0.79±0.04	0.85±0.03	0.27
Potassium (mmol/L)	4.2±0.1	4.1±0.0	0.21

Data reported as mean ± standard error mean, percentage, or median [interquartile range].

Abbreviations: ART, antiretroviral therapy; N/A, not applicable; PI, protease inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; HCV, hepatitis C virus; BMI, body mass index; BAI, body adipose index; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; TAT, total adipose tissue; HOMA-IR, homeostatic model assessment of insulin resistance

Supplemental Table 3. Model to Assess Determinants of Serum Aldosterone among HIV-Infected Individuals During RAAS Activation

Serum Aldosterone (ng/dL)	β Estimate	P Value
	(R^2=0.59; P=0.007)	
BNP (pg/mL)	-0.3545	0.04
PRA (ng/mL/hr)	0.4824	0.005
Urine Sodium (mmol/24hr)	-0.0006	0.79
MAP (mmHg)	-0.0053	0.56

R^2 represents the coefficient of determination and the proportion of variance explained by the model. P value represents significance by the whole model ANOVA test.

Performed under conditions of equivalent low sodium intake for both groups as described in the text.

Abbreviations: BNP, brain natriuretic peptide; PRA, plasma renin activity; MAP, mean arterial pressure